CTIS2022-502308-66-00进行中（未招募）1 期
A Phase 1/2, randomized, dose-finding/dose-confirmation study to evaluate the reactogenicity, safety and immunogenicity of mRNA-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults - 217884
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,272
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •A male or female between and including 18 and 50 years of age in Phase 1 and between and including 18 and 85 years of age (YA: 18-64; OA: 65-85) in Phase 2 at the time of the study intervention administration., Healthy participants or medically stable patients as established by medical history, clinical examination and safety laboratory assessments. Participants with chronic medical conditions with or without specific treatment (e.g., chronic metabolic, cardiac, pulmonary, renal, hepatic, neurologic, and hematologic diseases) are allowed to participate in this study if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrollment., Body mass index (BMI) = 18 kg/m² and = 35kg/m², Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow up visits)., Written informed consent obtained from the participant prior to performing any study-specific procedure., Female participants of non-childbearing potential may be enrolled in the study., Female participants of childbearing potential may be enrolled in the study if the participant: 1) has practiced adequate contraception for 28 days prior to study intervention administration, and 2)has a negative pregnancy test on the day of study intervention administration, and 3) has agreed to continue adequate contraception for at least 1 month after study intervention administration.
排除标准
- •Only in Phase 1: Any clinically significant* hematological, biochemical, urinalysis or HbA1c laboratory abnormality. *The investigator should use his/her clinical judgment to decide which abnormalities are clinically significant., Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. Prior/Concomitant therapy, Administration of an influenza vaccine (including any of the study investigational vaccines) within 180 days before enrollment or planned administration within 28 days (Day 29) after the study intervention administration., Phase 1: Administration of a vaccine not foreseen by the study protocol in the period starting 28 days (Day -28) before the study intervention administration, or planned administration within 28 days (Day 29) after the study intervention administration*. Phase 2: Administration of a vaccine not foreseen by the study protocol in the period starting 15 days (Day -15) before the study intervention administration, or planned administration within 28 days (Day 29) after the study intervention administration*. *In case emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced to 7 days if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly., Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention during the period beginning 30 days before the study intervention administration, or their planned use during the study period., Administration of long-acting immune-modifying drugs within 90 days before enrollment or planned use at any time during the study period (e.g., infliximab)., Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration, or planned administration during the study period. Administration of monoclonal antibodies specifically directed against the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), for treatment of COVID-19 disease is allowed., Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the study intervention administration. For corticosteroids, this will mean prednisone equivalent = 20 mg/day. Inhaled, topical and intraarticular steroids are allowed., Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device)., Pregnant or lactating female., Bedridden participants., Participant tested positive for influenza by local health authority-approved testing methods within 180 days prior to Day 1., Female planning to become pregnant or planning to discontinue contraceptive precautions within the 1-month post-dosing period., Alcoholism or substance use disorder within the past 24 months based on the presence of 2 or more of the following abuse criteria: hazardous use, social/interpersonal problems related to use, neglect of major roles to use, withdrawal, toleranc
研究者
相似试验
进行中（未招募）
1 期
A phase I/II study to evaluate the safety of and immunological response to a vaccine candidate (VLA2001) against COVID-19ISRCTN82411169Valneva (Austria)150
未知
2 期
A phase 2, randomized, double-blind, dose finding study of DS-8500a in Japanese patients with type 2 diabetes mellitusType 2 Diabetes MellitusJPRN-jRCT2080223014DAIICHISANKYO Co.,Ltd.335
进行中（未招募）
不适用
A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a polyclonal anti-RhD immunoglobulin in healthy RhD negative volunteersProphyllaxis against RhD isoimmunisation during pregnancy (anti-D prophylaxis)Treatment of RhD negative individuals after incompatible transfusions with blood components containing RhD-positive red blood cells.MedDRA version: 9.1Level: LLTClassification code 10019513Term: Hemolytic disease of fetus or newborn, due to isoimmunizationMedDRA version: 9.1Level: LLTClassification code 10044360Term: Transfusion with incompatible bloodEUCTR2009-011017-24-DEFB Biotechnologies
招募中
2 期
AVX754 (nucleoside reverse transcriptase inhibitor) to treat drug resistant HIVHIV InfectionsACTRN12605000742673Avexa Ltd60
进行中（未招募）
1 期
Phase II, randomized, pharmokinetic, dose finding, and dose frequency determination using rt-PA in intraventricular hemorrhage - CLEAR IVHIntracerebral haemorrhage with intraventricular extensionEUCTR2004-000919-26-GBewcastle upon Tyne Hospitals NHS Trust52